Media White-wash Flawed Study Of Cancer Drug Approvals
The media's reporting on a recent study of the regulatory approvals of cancer drugs was uniformly, inexcusably sloppy. The New York Times' coverage was typical. It began:New cancer drugs are approved in just six months on average in the United States, half the time it takes for the same drugs to be approved in Europe, a new report finds.The analysis, published online this month by the journal ...

SEC adds insider trading charge vs FDA chemist
Federal regulators on Thursday expanded their civil insider-trading charges against a chemist with the Food and Drug Administration accused of using confidential FDA information on pending drug approvals to profit from trades of drug companies' stock.